The Additive Effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis.

Trial Profile

The Additive Effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Menatetrenone (Primary) ; Phytomenadione (Primary) ; Alendronic acid; Bisphosphonates
  • Indications Metabolic bone diseases; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms VITKANDOP
  • Most Recent Events

    • 31 Jul 2017 Planned number of patients changed from 150 to 105.
    • 31 Jul 2017 Planned End Date changed from 30 Apr 2017 to 1 Dec 2019.
    • 31 Jul 2017 Planned primary completion date changed from 1 Jun 2013 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top